Anti-cancer and anti-hepatitis C virus NS5B polymerase activity of etodolac 1,2,4-triazoles

References

• Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer – a player that's defining the rules. J Natl Cancer Inst 2002;94:545–6
   PubMed Web of Science ®Google Scholar
• Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002;963:13–20
   PubMed Web of Science ®Google Scholar
• Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127:218–24
   PubMed Web of Science ®Google Scholar
• Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688–96
   PubMed Web of Science ®Google Scholar
• Küçükgüzel ŞG, Coşkun İ, Aydın S, et al. Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents. Molecules 2013;18:3595–614
   PubMed Web of Science ®Google Scholar
• Demerson CA, Humber LG, Abraham NA, et al. Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 1983;26:1778–80
   PubMed Web of Science ®Google Scholar
• Behari J, Zeng G, Otruba W, et al. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol 2007;46:849–57
   PubMed Web of Science ®Google Scholar
• Liu W, Nakamura H, Tsujimura T, et al. Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 2006;97:768–73
   PubMed Web of Science ®Google Scholar
• Cheng J, Imanishi H, Liu W, et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004;95:666–73
   PubMed Web of Science ®Google Scholar
• Duran A, Doğan HN, Rollas S. Synthesis and preliminary anticancer activity of new 1,4-dihydro–3-(3-hydroxy-2-naphthyl)-4-substituted-5H-1,2,4-triazoline-5-thiones. Il Farmaco 2002;57:559–64
   PubMedGoogle Scholar
• Li Z, Gu Z, Yin K, Zhang R, et al. Synthesis of substituted-phenyl-1,2,4-triazol-3-thione analogues with modified D-glucopyranosyl residues and their antiproliferative activities. Eur J Med Chem 2009;44:4716–20
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Lim K, Ciszewski G, et al. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem 2004;47:6603v8
   Google Scholar
• LaPorte MG, Draper TL, Miller LE, et al. The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2010;20:2968–73
   PubMed Web of Science ®Google Scholar
• Çıkla P, Arora P, Basu A, et al. etodolac thiosemicarbazides: a novel class of hepatitis C virus NS5B polymerase inhibitors. Marmara Pharm J 2013;17:138–46
   PubMedGoogle Scholar
• Çıkla P, Özsavcı D, Bingöl-Özakpınar Ö, et al. Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. Arch Pharm (Weinheim) 2013;346:367–79
   PubMed Web of Science ®Google Scholar
• Küçükgüzel ŞG, Süzgün P. Synthesis of thiosemicarbazides and triazoles derived from etodolac. Patent WO 2014/003694 A1; 2014
   Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–38
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Myers TG, O’Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343–9
   PubMed Web of Science ®Google Scholar
• Kaushik–Basu N, Bopda-Waffo A, Basu A, et al. 4-Thiazolidinones: a novel class as hepatitis C virus NS5B polymerase inhibitors. Front Biosci 2008;13:3857–68
   PubMed Web of Science ®Google Scholar
• Kaushik-Basu N, Bopda-Waffo A, Talele TT, et al. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res 2008;36:1482–96
   PubMed Web of Science ®Google Scholar
• Li H, Tatlock J, Linton A, et al. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo [1,5-a]pyrimidin-2-yl) methyl)-4-hydroxy-5,6-dihydropyran-2-ne (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 2009;52:1255–8
   PubMed Web of Science ®Google Scholar
• Nichols DB, Leão RA, Basu A, et al. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des 2013;81:607–14
   PubMed Web of Science ®Google Scholar
• Küçükgüzel ŞG, Rollas S, Erdeniz H, Kiraz M. Synthesis, characterization and antimicrobial evaluation of ethyl 2-arylhydrazono-3-oxobutyrates. Eur J Med Chem 1999;34:153–60
   Web of Science ®Google Scholar
• Rollas S, Kalyoncuoğlu N, Sur-Altiner D, Yeğenoğlu Y. 5-(4-Aminophenyl)-4-substituted-2,4-dihydro-3H-1,2,4-triazole-3-thiones: synthesis and antibacterial and antifungal activities. Pharmazie 1993;48:308–9
   PubMed Web of Science ®Google Scholar
• Küçükgüzel İ, Küçükgüzel ŞG, Rollas S, et al. Synthesis of some 3-(arylalkylthio)-4-alkyl/aryl-5-(4-aminophenyl)-4H-1,2,4-triazole derivatives and their anticonvulsant activity. Il Farmaco 2004;59:893–901
   PubMedGoogle Scholar
• Küçükgüzel ŞG, Küçükgüzel İ, Tatar E, et al. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur J Med Chem 2007;42:893–901
   PubMed Web of Science ®Google Scholar
• Salgın-Gökşen U, Gökhan-Kelekçi N, Göktaş Ö, et al. 1-Acylthiosemicarbazides, 1,2,4-triazole-5(4H)-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: synthesis, analgesic-anti-inflammatory and antimicrobial activities. Bioorg Med Chem 2007;15:5738–51
   PubMed Web of Science ®Google Scholar
• Küçükgüzel I, Tatar E, Küçükgüzel SG, et al. Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur J Med Chem 2008;43:381–92
   PubMed Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601
   PubMed Web of Science ®Google Scholar
• Kast RE. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol 2007;24:1–6
   PubMed Web of Science ®Google Scholar
• Küçükgüzel ŞG, Süzgün P, Arora P, et al. Etodolac derivatives as HCV NS5B polymerase inhibitors. Patent WO 2014/003693 A1; 2014
   Google Scholar